Compass Diversified (NYSE:CODI) Q3 2025 Earnings call January 14, 2026 05:00 PM ET Company ParticipantsBen Tapper - VP of Investor RelationsStephen Keller - Managing DirectorElias Sabo - CEOConference Call ParticipantsChris Kennedy - AnalystLawrence Solow - AnalystLance Vitanza - AnalystMatt Koranda - AnalystPat Maciariello - AnalystTimothy DeAgostino - AnalystOperatorAt this time, I would like to turn the call over to Ben Tapper, Vice President, Investor Relations. Ben, please go ahead.Ben TapperThank you, ...

J.P. Morgan 44th Annual Healthcare Conference Corporate Overview January 2026 Disclaimer and FLS This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc's expectations with respect to its preclinical studies, clinical trials and research and development programs, in particular with respect to bitopertin, DISC-0974 and DISC-3405, and any developments or resul ...

Forward looking statements Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statement ...

Financial Highlights - The company anticipates near-term milestones of up to $440 million for global GEA approvals[12] - The company has received $400 million in upfront and milestone payments to date[12] - Future potential regulatory and commercial milestones are valued at $13 billion[12] - Ziihera has a peak sales potential of over $20 billion[12] - The company reported revenues of $103 million for 2025[27] Pipeline and Partnerships - The company has potential future milestone payments of up to $434 million with Phase 3 partners[16] - The company has potential future milestone payments of up to $11 billion with Phase 1 partners[16] - The company has potential future milestone payments of up to $313 million with Phase 1 partners[16] - The company has potential future milestone payments of up to $230 million with Preclinical partners[16] Strategic Outlook - The company's cash resources of over $270 million provide a runway beyond 2028[27]

Arcus Biosciences J.P. Morgan Healthcare Conference 2026 Oncology and Immunology Portfolio January 14, 2026 Forward-looking Statements/Safe Harbor Forward-Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this presentation that are not historical facts are forward-looking statements, including ...

Financial Performance & Guidance - GeneDx reported preliminary full year 2025 revenue of $427 million, aligning with previous guidance of $425 to $428 million[73] - The company experienced a 54% growth in exome and genome revenue for full year 2025 (58% excluding a 2024 one-time benefit), exceeding previous guidance of 53% to 55%[73] - Exome and genome volume grew by 30.5% in 2025, meeting the minimum guidance of at least 30%[73] - Adjusted gross margin for 2025 was 71%, consistent with the guided range of 70% to 71%[73] - GeneDx anticipates revenue between $540 to $555 million for full year 2026[76] - The company projects a 33% to 35% growth in exome and genome revenue and volume for 2026[76] Market Position & Growth Strategy - GeneDx holds a leading position with 80% of geneticists preferring their services[8] - The company added 30% more tests to Infinity in 2025 than in the prior 24 years combined[13] - Over 30% of pediatric neurologists now order from GeneDx, indicating strong market penetration[39] - The company's dataset includes >2.5M genetic tests, >50% non-European descent, >8M health records, ~1M exomes & genomes, >7M phenotypic datapoints, and >60% have parental data[25] Expansion & Opportunities - GeneDx is expanding into new markets, including prenatal care, with GenomeDx Prenatal[35, 47] - The company sees a large unmet need in NICUs, where up to 60% of patients could benefit from rWGS, but less than 5% receive genetic testing today[44]

Financial Performance & Growth - Preliminary 2025 total revenue is expected to be approximately $100 million, representing a 25% year-over-year increase[12, 15, 18] - Core RNS System revenue grew by 25% in 2025, driven by sustained demand and increased utilization[12, 18] - Q4 2025 total revenue is estimated at $26.6 million, a 24% increase year-over-year[15] - Gross margin for 2025 is approximately 77.2%, an increase of 330 basis points year-over-year[15] - The company projects revenue between $98 million and $100 million for FY26, with RNS revenue growth of approximately 20-22% and gross margin around 81-82%[21] RNS System & Clinical Data - The RNS System has been used in over 8,000 patients[12] - The RNS System demonstrated a median seizure reduction of 75% at 9 years in the original FDA study results[35] - The RNS Post-Approval Study showed an 82% median seizure reduction at 3+ years[35, 37] - Preliminary NAUTILUS results showed an 18-month median seizure reduction of 77% in LGS patients[61] Market & Expansion - The annual target market opportunity is estimated at over $3.5 billion[12] - Approximately 1.2 million people in the U S have drug-resistant epilepsy (DRE)[25, 56] - The company is focused on expanding access to the RNS System in generalized epilepsy, pediatrics, and community channels[74]

Compass Diversified (NYSE:CODI) Q3 2025 Earnings call January 14, 2026 05:00 PM ET Speaker0At this time, I would like to turn the call over to Ben Tapper, Vice President, Investor Relations. Ben, please go ahead.Speaker2Thank you, and welcome to Compass Diversified's third quarter 2025 conference call. Representing the company today are Elias Sabo, Cody's Chief Executive Officer, and Stephen Keller, Cody's Chief Financial Officer. We are also joined by Zach Sawtelle, Chief Operating Officer for Compass Grou ...

Financial Data and Key Metrics Changes - Net sales grew 23% year over year to $22.7 million in Q4 2025, with full-year revenue increasing 24% to $80.6 million compared to fiscal 2024 [4][5][19] - Gross profit margin for Q4 was 37%, exceeding the 30% target, and for the full year, it was 33%, up from 29% in the prior year [4][5][18][19] - Adjusted EBITDA for Q4 was $2.6 million, compared to $908,000 in Q4 2024, and for the full year, it was $6.1 million, a significant increase from $838,000 in fiscal 2024 [18][19][21] Business Line Data and Key Metrics Changes - The company has shifted from being a product seller to a technology solutions provider, which has diversified its customer base and end markets [6][7] - Key initiatives include deepening relationships with existing customers, leveraging successes in established markets to penetrate new ones, and expanding value propositions for channel partners [8][10] Market Data and Key Metrics Changes - Demand in targeted end markets, including aerospace, stadiums, and transportation, remains strong, with over 130 projects supported in these categories [14][15] - The aerospace and defense market continues to perform well, driven by collaboration with customers to meet stringent requirements [15] Company Strategy and Development Direction - The company aims to diversify end markets, drive customer penetration, and launch new products to sustain strong sales growth and profitability in fiscal 2026 [6][11] - The focus is on operational excellence and innovation aligned with market demand, with a disciplined approach to resource allocation [16][17] Management's Comments on Operating Environment and Future Outlook - Management acknowledges uncertainties in the overall environment but remains confident in executing the long-term strategic plan [6][12] - The expectation for fiscal 2026 is another year of growth, with a similar trajectory to fiscal 2025, despite anticipated seasonality in Q1 [28][29] Other Important Information - The company reduced net debt by $4.6 million compared to last year, with a current ratio of approximately 1.7 to 1 [21][22] - Inventory levels were managed down to $13.7 million from $14.7 million last year, reflecting operational excellence [22][23] Q&A Session Summary Question: Growth trajectory for fiscal 2026 - Management expects another year of growth, with Q1 likely being the lowest quarter of the year due to seasonality [28][29] Question: Breakdown of gross margin expansion - The gross margin increase is attributed to a combination of product mix and higher sales volume, with significant cash flow impact as sales exceed $20 million [31][32] Question: Cost increases and mitigation strategies - Cost increases are nominal and include labor and benefits, with some mitigation possible through pricing and improved sales numbers [38][39] Question: Revenue contribution from diversified markets - Approximately 50% of sales now come from telecom and wireless, with the remaining from transportation, aerospace, and other sectors [53][54] Question: Backlog and bookings analysis - Backlog is expected to hit a low point in Q1 and then increase as project-based work resumes, with Q4 bookings aligning with expectations [55][56][59]

OPKO Health Conference Call Summary Company Overview - **Company**: OPKO Health - **Key Participants**: - Elias Zerhouni - President - Adam Logal - CFO - **Industry**: Biotechnology and Clinical Diagnostics Core Business Components - OPKO Health operates a diverse range of businesses, including: - Clinical diagnostics through BioReference Health - Biotech operations via ModeX Therapeutics, focusing on therapeutics and divesting from clinical diagnostics to improve profitability [6][15] Financial Performance and Strategy - OPKO has divested approximately 40% of its clinical diagnostic business to enhance profitability, focusing on operations in New York and New Jersey [6][15] - The company is nearing break-even and profitability with its remaining clinical diagnostic business, particularly with the 4Kscore cancer diagnostic test, which has shown over 15% growth in testing [7][17] - Guidance for 2026 indicates a projected revenue growth of 3%-5% from a base of approximately $300 million, with a focus on operating efficiency rather than deep investment in commercial operations [18] Key Products and Developments - **4Kscore Test**: - Aids in identifying patients at high risk for aggressive prostate cancer, with a market potential of $25-$30 million [20][21] - Recently received FDA clearance to remove the requirement for a digital rectal exam, potentially increasing adoption [21] - **ModeX Therapeutics**: - Licensed an Epstein-Barr Virus (EBV) vaccine to Merck for $50 million upfront and potential milestones of $870 million [9][10] - The vaccine is in phase one trials, with significant potential for treating cancer and multiple sclerosis [10][25] - **Pipeline Products**: - MDX-2001: A cancer solid tumor product nearing phase 1B trials, targeting multiple cancer types [11][32] - MDX-2004: A trispecific antibody aimed at rejuvenating the immune system, currently in clinical trials [12][42] - Collaboration with Regeneron to develop multiple programs in obesity, metabolism, and cancer [13][52] Milestones and Future Outlook - The company anticipates significant milestones tied to the progression of its vaccine and therapeutic candidates, with potential financial milestones upon entering phase two trials [27][31] - The partnership with Regeneron is expected to yield candidates by the end of the year or early next year, with a focus on combination therapies [53][54] Risk Management and Clinical Trials - OPKO is managing risks associated with clinical trials, particularly concerning cytokine release syndrome (CRS) through established protocols and dose management strategies [36][39] - The company is focused on ensuring safety and efficacy in its trials, with ongoing assessments to determine the most responsive cancer types for its therapies [32][35] Conclusion - OPKO Health is strategically repositioning itself towards a more therapeutics-focused model while maintaining a profitable clinical diagnostics segment. The company is poised for growth with a rich pipeline of products and strategic partnerships that could lead to significant advancements in the biotech space over the next few years [15][30]